Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$48M
- −47.5% YoY · −15.9% QoQ
- EPS (diluted)
- −$0.45
- −45.2% YoY · −18.4% QoQ
Source: XBRL data from the Oric Pharmaceuticals, Inc. (ORIC) Q3 2026 10-Q on SEC EDGAR. USD.
Oric Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product candidates commercialized
- Net loss $48.1M vs $32.6M YoY, operating expenses $51.6M vs $36.7M
- Rinzimetostat R&D $21.2M, up $15.6M YoY, largest program spending
- Operating cash use $106.0M, cash and investments sufficient into second half of 2028
- Himalayas-1 Phase 3 underway, Redwood-1 planned first half of 2027, funding needs and development costs rising
Risk Factors
- New regulatory risk: 2026 FDA workforce reductions and policy changes could delay reviews, inspections, and regulatory correspondence
- Most materially updated compliance risk: CMS proposed 2029 Medicare negotiation rules, increasing uncertainty over future drug pricing
- Operational risk: Competitors’ greater AI use in pharmaceutical development could disadvantage ORIC’s limited AI adoption
- Financial risk: $345.4 million in cash, equivalents, and investments expected to fund operations into the second half of 2028
- Legal risk: EU GDPR violations could trigger fines up to €20,000,000 or 4% of worldwide annual turnover
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oric Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.